PAGE: Canada

Canada

Immunocidin® (canine)

Immunocidin, mycobacterium cell wall fraction (MCWF) immunostimulant, is CFIA-approved for the intratumoral treatment of mixed mammary tumor and mammary adenocarcinoma in dogs.

Available Presentations: 2.5 mL vial

Download the product brochure. Download a summary of case reports on product efficacy.

Immunocidin, mycobacterium cell wall fraction (MCWF) immunostimulant, is approved by the CFIA for the treatment of mixed  mammary tumor and mammary adenocarcinoma in dogs.

Although Immunocidin is administered by intratumoral injection, the response is generalized and untreated sites frequently undergo regression as well.

Why use Immunocidin?

• It has a high tumor-free survival rate

• It is well-tolerated by dogs, including older animals

• It provides a treatment option for dogs that are poor surgical risks

• It minimizes the side effects associated with chemotherapeutic treatments

• It may be used safely in-clinic with no risk to clinic personnel

• It is an economical treatment option for your clients

• It has an excellent safety profile

Product insert

MSDS

For veterinarians to purchase product:

Phone: 1-613-308-9788

Email: sales@NovaVive.ca